Bayer Contraceptives Win Advisory Committee Backing As Panel Rejects Call For Comparative Effectiveness
This article was originally published in The Pink Sheet Daily
Executive Summary
In a 15-11 vote, FDA advisory panel members split on whether drugs containing progestin drospirenone should be judged on absolute risk, or whether their potentially higher risk than other birth control pills should be offset by benefits beyond those provided by alternatives.